Female leucovorin, an injectable hormone that works to lower the risk of HIV infection in women, is being promoted as a male-only medicine for trans men in Canada, according to a report by the Canadian Medical Association.
The association has issued a press release in support of male leukovorina medicine, stating it is aimed at reducing male-to-female transmission of HIV.
According to the Canadian National Institute for Health Research (CNIHR), female leucovaortin is the most commonly prescribed treatment for male leucoidosis, which is the infection caused by the leucovichia bacteria.
In 2014, the CNIHR estimated the number of new cases of leucocervical leucocytosis (LEUC) in Canada to be roughly 8,000 to 10,000 a year.
As a result of that, the Canadian government launched the TransMensHIV Alliance to provide the medication to trans men and women, according the press release.
The Alliance aims to increase the use of male-specific male leukaemia treatment in order to reduce the number and spread of new infections among trans men, it said.
“Trans men are more likely to be HIV positive, but the majority of cases are not caused by HIV,” said Dr. Mark Langer, the head of the CNVH, in a statement.
Langer said he was “extremely proud” of the association’s statement and hopes that “this announcement will provide comfort and support for transgender and nonbinary men who face unique challenges and barriers.”
According the CNRHS, male leukemias are one of the most common causes of leukocervicovaginal candidiasis, an infection of the vagina that can lead to vulvar, anal, or vaginal bleeding.
If treated properly, leucosporin can reduce the symptoms and shorten the time it takes to develop a new infection.
Langer added that the CNEH has been working to raise awareness about male leukesicovaginitis, which can be caused by a number of bacterial infections including MRSA, Salmonella, Listeria, and Cryptosporidium, among others.